Molecular mechanisms in aging and current strategies to counteract sarcopenia

Current Aging Science

Volumn 3, Issue 2, 2010, Pages 90-101

  Sakuma, Kunihiro ^a   Yamaguchi, Akihiko ^b  

^a TOYOHASHI UNIVERSITY OF TECHNOLOGY   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Myostatin; Sarcopenia; Skeletal muscle; SRF; Testosterone

Indexed keywords

AMINO ACID; ATROGIN 1; BRANCHED CHAIN AMINO ACID; CREATINE; CREATINE MONOPHOSPHATE; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; ESSENTIAL AMINO ACID; ESTROGEN; GROWTH HORMONE; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MUSCLE RING FINGER 1 PROTEIN; MYO 29; MYOSTATIN; NOTEXIN; PF 354; PROTEIN INHIBITOR; PROTEIN KINASE B; RECOMBINANT SOMATOMEDIN C; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SERUM RESPONSE FACTOR; SOMATOMEDIN C; TESTOSTERONE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID;

AGE; AGING; APOPTOSIS; ARTHRALGIA; ARTICLE; BECKER MUSCULAR DYSTROPHY; CALORIC RESTRICTION; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EDEMA; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GYNECOMASTIA; HOMEOSTASIS; HUMAN; MITOCHONDRION; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RESISTANCE TRAINING; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

AGED; AGED, 80 AND OVER; AGING; AMINO ACIDS; ANIMALS; APOPTOSIS; CALORIC RESTRICTION; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MITOCHONDRIA, MUSCLE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSTATIN; RESISTANCE TRAINING; SARCOPENIA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77953745513     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811003020090     Document Type: Article

References (178)

1. Candow DG and Chilibeck PD. Differences in size, strength, and power of upper and lower body muscle groups in young and older men. J Gerontol A Biol Sci Med Sci 2005; 60: 148-56.
2. Baumgartner RN, Waters DL, Gallagher D, Morley JE and Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123-36.
3. Melton 3rd LJ, Khosla S, Crowson CS, O'Fallon WM and Riggs BL. Epidemiology of sarcopenia. J Am Geriat Soc 2000; 48: 625-30.
4. Poehlman ET, Toth MJ and Fonong T. Exercise, substrate utilization and energy requirements in the elderly. Int J Obes Relat Metab Disord 1995; 19: S93-S6.
5. Griffiths RD. Muscle mass, survival and the elderly ICU patient. Nutrition 1996; 12: 456-8.
6. Janssen I, Shepard DS, Katzmarzyk PT and Roubenoff R. The healthcare costs of sarcopenia in the Unitated States. J Am Geriatr Soc 2004; 52: 80-5.
7. Lexell J. Ageing and human muscle: observations from Sweden. Can J Appl Physiol 1993; 18: 2-18.
8. Roubenoff R and Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000; 55: M716-M24.
9. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 1014-9.
10. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5: 87-90.
11. Lai K-MV, Gonzalez M, Poueymirou WT, Kline WO, Na E, Zlotchenko E, et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004; 24: 9295-304.
12. Terada N, Patel HR, Takase K, Kohno K, Nairn AC and Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci USA 1994; 91: 11477-81.
13. Gingras AC, Raught B and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807-26.
14. S6K, and ERK1/2 phosphorylation in aged skeletal muscle. J Appl Physiol 2004; 97: 243-8.
15. Kimball SR, O'Malley JP, Anthony JC, Crozier SJ and Jefferson LS. Assessment of biomarkers of protein anabolism in skeletal muscle during the life span of the rat: sarcopenia despite elevated protein synthesis. Am J Physiol Endocrinol Metab 2004; 287: E772-80.
16. Léger B, Derave W, De Bock K, Hespel P and Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 2008; 11: 163-75.
17. Haddad F and Adams GR. Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J Appl Physiol 2006; 100: 1188-203.
18. Funai K, Parkington JD, Carambula S and Fielding RA. Age-associated decrease in contraction-induced activation of downstream targets of Akt/mTOR signaling in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1080-R6.
19. Thomson DM and Gordon SE. Impaired overload-induced muscle growth is associated with diminished translational signaling in aged rat fast-twitch skeletal muscle. J Physiol 2006; 574: 291-305.
20. Treisman R. Identification and purification of a polypeptide that binds to the c-fos serum response element. EMBO J 1987; 6: 2711-7.
21. Pipes GC, Creemers EE and Olson EN. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 2006; 20: 1545-56.
22. Charvet C, Houbron C, Parlakian A, Giordani J, Lahoute C, Bertrand A, et al. New role for serum response factor in postnatal skeletal muscle growth and regeneration via the interleukin 4 and insulin-like growth factor 1 pathways. Mol Cell Biol 2006; 26: 6664-74.
23. Sakuma K, Nishikawa J, Nakao R, Nakano H, Sano M and Yasuhara M. Serum response factor plays an important role in the mechanically overloaded plantaris muscle of rats. Histochem Cell Biol 2003; 119: 149-60.
24. Gordon SE, Flück M and Booth FW. Skeletal muscle focal adhesion kinase, paxillin, and serum response factor are loading dependent. J Appl Physiol 2001; 90: 1174-83.
25. Gauthier-Rouviére C, Vandromme M, Tuil D, Lautredou N, Morris M, Soulez M, et al. Expression and activity of serum response factor is required for expression of the muscle-determining factor MyoD in both dividing and differentiating mouse C2C12 myoblasts. Mol Biol Cell 1996; 7: 719-29.
26. Sakuma K, Nakao R, Inashima S, Hirata M, Kubo T and Yasuhara M. Marked reduction of focal adhesion kinase, serum response factor and myocyte enhancer factor 2C, but increase in RhoA and myostatin in the hindlimb dy mouse muscles. Acta Neuropath (Berl) 2004; 108: 241-9.
27. Lahoute C, Sotiropoulos A, Favier M, Guillet-Deniau I, Charvet C, Ferry A, et al. Premature aging in skeletal muscle lacking serum response factor. PLoS One 2008; 3: e3910.
28. Sakuma K, Akiho M, Nakashima H, Akima H and Yasuhara M. Age-related reductions in expression of serum response factor and myocardin-related transcription factor A in mouse skeletal muscles. Biochim Biophys Acta Mol Basis Dis 2008; 1782: 453-61.
29. Kuwahara K, Barrientos T, Pipes GC, Li S and Olson EN. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Mol Cell Biol 2005; 25: 3173-81.
30. Cen B, Selvaraj A, Burgess RC, Hitzler JK, Ma Z, Morris SW, et al. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Mol Cell Biol 2003; 23: 6597-608.
31. Wang DZ, Li S, Hockemeyer D, Sutherland L, Wang Z, Schratt G, et al. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci USA 2002; 99: 14855-60.
32. Carson JA and Wei L. Integrin signaling's potential for mediating gene expression in hypertrophying skeletal muscle. J Appl Physiol 2000; 88: 337-43.
33. Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 2005; 308: 1599-603.
34. Lamon S, Wallace MA, Léger B and Russell AP. Regulation of STARS and its downstream targets suggest a novel pathway involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2009; 587: 1795-803.
35. McPherron AC, Lawler AM and Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387: 83-90.
36. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast differentiation. J Biol Chem 2000; 275: 40235-43.
37. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S and Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002; 277: 49831-40.
38. Yang W, Zhang Y, Li Y, Wu Z and Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 pathway and is antagonized by insulin-like growth factor 1. J Biol Chem 2007; 282: 3799-808.
39. Allen DL and Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 2007; 292: C188-C99.
40. Wehling M, Cai B and Tidball JG. Modulation of myostatin expression during modified muscle use. FASEB J 2000; 14: 103-10.
41. Sakuma K, Watanabe K, Sano M, Uramoto I and Totsuka T. Differential adaptation of growth and differentiation factor 8/myostatin, fibroblast growth factor 6 and leukemia inhibitory factor in overloaded, regenerating, and denervated rat muscles. Biochim Biophys Acta Mol Cell Res 2000; 1497: 77-88.
42. Sakuma K, Watanabe K, Hotta N, Koike T, Ishida K, Katayama K, et al. The adaptive responses in several mediators linked with hypertrophy and atrophy of skeletal muscle after lower limb unloading in humans. Acta Physiol(Oxf) 2009; 197: 151-9.
43. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, et al. Organization of the human myostatin gene and expression in health men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 1998; 95: 14938-43.
44. Carlson ME, Hsu M and Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors is old muscle stem cells. Nature 2008; 454: 528-32.
45. Attaix D, Aurousseau E, Combaret L, Kee A, Larbaud D, Ralliére C, et al. Ubiquitin-proteasome-dependent proteolysis in skeletal muscle. Reprod Nutr Dev 1998; 38: 153-65.
46. Mitch WE and Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335: 1897-905.
47. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18: 39-51.
48. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-8.
49. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-41.
50. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-I/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14: 395-403.
51. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119: 285-9.
52. Welle S, Brooks AL, Delehany JM, Needler N and Thornton CA. Gene expression profile of aging in human muscle. Physiol Genomics 2003; 14: 149-59.
53. Whitman SA, Wacker MJ, Richmond SR and Godard MP. Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal muscle wasting with age. Pflügers Arch 2005; 450: 437-46.
54. Pattison JS, Folk LC, Madsen RW, Childs TE and Booth FW. Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle. Physiol Genomics 2003; 15: 34-43.
55. Clavel S, Coldefy AS, Kurkdjian E, Salles J, Margaritis I and Derijard B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat tibialis anterior muscle. Mech Ageing Dev 2006; 127: 794-801.
56. DeRuisseau KC, Kavazis AN and Powers SK. Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Exp Gerontol 2005; 40: 526-31.
57. Edström E, Altun M, Hägglund M and Ulfhake B. Atrogin- 1/MAFbx and MuRF1 are downregulated in ageing-related loss of skeletal muscle. J Gerontol A Biol Sci Med Sci 2006; 61: 663-74.
58. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 2007; 21: 140-55.
59. Marzetti E, Lawler JM, Hiona A, Manini T, Seo AY and Leeuwenburgh C. Modulation of age-induced apoptotic signaling and cellular remodeling by exercise and calorie restriction in skeletal muscle. Free Radic Biol Med 2008; 44: 160-8.
60. Wang C and Youle RJ. The role of mitochondria in apoptosis. Ann Rev Genet 2009; 43: 95-118.
61. Adhihetty PJ, O'Leary MF and Hood DA. Mitochondria in skeletal muscle: adaptable rheostats of apoptotic susceptibility. Exerc Sport Sci Rev 2008; 36: 116-21.
62. Dirks A and Leeuwenburgh C. Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 2002; 282: R519-R27.
63. Dirks AJ and Leeuwenburgh C. Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radic Biol Med 2004; 36: 27-39.
64. Jezek P and Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol 2005; 37: 2478-503.
65. Yakes FM and Van HB. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514-9.
66. Wei YH and Lee HC. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp Biol Med (Maywood) 2002; 227: 671-82.
67. Bua EA, McKiernan SH, Eanagat J, McKenzie D and Aiken JM. Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J Appl Physiol 2002; 92: 2617-24.
68. Coral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF and Wallace DC. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 1992; 2: 324-9.
69. Wanagat J, Cao Z, Pathare P and Aiken JM. Mitochondrial DNA deletion mutations colocalize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia. FASEB J 2001; 15: 322-32.
70. Cortopassi GA and Wong A. Mitochondria in organismal aging and degeneration. Biochim Biophys Acta 1999; 1410: 183-93.
71. Pollack M and Leeuwenburgh C. Apoptosis and aging: role of the mitochondria. J Gerontol A Biol Sci Med Sci 2001; 56: B475-B82.
72. Song W, Kwak HB and Lawler JM. Exercise training attenuates age-induced changes in apoptotic signaling in rat skeletal muscle. Antioxid Redox Signal 2006; 8: 517-8.
73. Esmarck B, Andersen JL, Olsen S, Richter EA, Mizuno M and Kjaer M. Timing of postexercise protein intake is important for muscle hypertrophy with resistance training in elderly humans. J Physiol 2001; 535: 301-11.
74. Fiatarone MA, O'Neil EF, Ryan ND, Clements KM, Solares GR, Nelson ME, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330: 1769-75.
75. Fiatarone MA, Ding W, Manfredi TJ, Solares GS, O'Neil EF, Clements KM, et al. Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders. Am J Physiol Endocrinol Metab 1999; 277: E135-43.
76. Hunter GR, McCarthy JP and Bamman MM. Effects of resistance training on older adults. Sports Med 2004; 34: 329-48.
77. Raue U, Slivka D, Jemiolo B, Hollon C and Trappe S. Myogenic gene expression at rest and after a bout of resistance exercise in young (18-30 yr) and old (80-89 yr) women. J Appl Physiol 2006; 101: 53-9.
78. Pedersen BK. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essay Biochem 2006; 42: 105-17.
79. Parise G, Brose AN and Tarnopolsky MA. Resistance exercise training decreases oxidative damage to DNA and increases cytochrome oxidase activity in older adults. Exp Gerontol 2005; 40: 173-80.
80. Hasten DL, Pak-Loduca J, Obert KA and Yarasheski KE. Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78-84 and 23-32 yr olds. Am J Physiol Endocrinol Metab 2000; 278: E620-E6.
81. Yarasheski KE, Pak-Loduca J, Hasten DL, Obert KA, Brown MB and Sinacore DR. Resistance exercise training increases mixed muscle protein synthesis rate in frail women and men > 76 yr old. Am J Physiol Endocrinol Metab 1999; 277: E118-E25.
82. Williamson D, Gallagher P, Harber M, Hollon C and Trappe S. Mitogen-activated protein kinase (MAPK) pathway activation: effects of age and acute exercise on human skeletal muscle. J Physiol 2003; 547: 977-87.
83. Mayhew DL, Kim JS, Cross JM and Bamman MM. Translational signaling responses preceding resistance training-mediated myofibers hypertrophy in young and old humans. J Appl Physiol 2009; 107: 1655-62.
84. Kosek DJ, Kim JS, Petrella JK, Cross JM and Bamman MM. Efficacy of 3 day/wk resistance training on myofiber hypertrophy and myogenic mechanisms in young vs. older adults. J Appl Physiol 2006; 101: 531-44.
85. Bradley L, Yaworsky PJ and Walsh FS. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci 2008; 65: 2119-24.
86. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420: 418-21.
87. Holzbaur EL, Howland DS, Weber N, Wallace K, She Y, Kwak S, et al. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis 2006; 23: 697-707.
88. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63: 561-71.
89. Minetti GC, Colussi C, Adami R, Serral C, Mozzetta C, Parente V, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nature Med 2006; 12: 1147-50.
90. Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 2009; 9: 608-16.
91. Siriett V, Platt L, Salerno MS, Ling N, Kambadur R and Sharma M. Prolonged absence of myostatin reduces sarcopenia. J Cell Physiol 2006; 209: 866-73.
92. Lebrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM and Brown TA. Myostatin inhibition enhances the effects on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009; 64: 940-8.
93. Timmerman KL and Volpi E. Amino acid metabolism and regulatory effets in aging. Curr Opin Clin Nutr Metab Care 2008; 11: 45-9.
94. Henderson GC, Irving BA and Nair KS. Potential application of essential amino acid supplementation to treat sarcopenia in elderly people. J Clin Endocrinol Metab 2009; 94: 1524-6.
95. Paddon-Jones D and Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Nutr Metab Care 2009; 12: 86-90.
96. Tipton KD, Ferrando AA, Phillips SM, Doyle D, Jr. and Wolfe RR. Postexercise net protein synthesis in human muscle from orally administered amino acids. Am J Physiol Endocr Metab 1999; 276: E628-34.
97. Dreyer HC, Drummond MJ, Pennings B, Fujita S, Glynn EL and Chinkes DL. Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Endocr Metab 2008; 294: E392-E400.
98. Combaret L, Dardevet D, Rieu I, Pouch M-N, Béchet D, Taillandier D, et al. A leucine-supplemented diet restores the defective postprandial inhibition of proteasome-dependent proteolysis in aged rat skeletal muscle. J Physiol 2005; 569: 489-99.
99. Drummond MJ, Dreyer HC, Pennings B, Fry CS, Dhanani S, Dillon EL, et al. Skeletal muscle protein anabolic response to resistance exercise and essential amino acids is delayed with aging. J Appl Physiol 2008; 104: 1452-61.
100. Walrand S, Short KR, Bigelow ML, Sweatt AJ, Hutson SM and Nair KS. Functional impact of high protein intake on healthy elderly people. Am J Physiol Endocrinol Metab 2008; 295: E921-E8.
101. Godard MP, Williamson DL and Trappe SW. Oral amino-acid provision does not affect muscle strength or size gains in older men. Med Sci Sports Exerc 2002; 34: 1126-31.
102. Welle S and Thornton CA. High-protein meals do not enhance myofibrillar synthesis after resistance exercise in 62- to 75-yr-old men and women. Am J Physiol Endocrinol Metab 1998; 274: E677-E83.
103. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A and Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab 2006; 291: E381-E7.
104. Solerte SB, Gazzaruso C, Bonacasa R, Rondanelli M, Zamboni M, Basso C, et al. Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia. Am J Cardiol 2008; 101(suppl): 69E-77E.
105. Dillon EL, Sheffield-Moore M, Paddon-Jones D, Gilkison C, Sanford AP, Casperson SL, et al. Amino acid supplementation increases lean body mass, basal muscle protein synthesis, and insulin-like growth factor-I expression in older women. J Clin Endocrinol Metab 2009; 94: 1630-7.
106. Verhoeven S, Vanschoonbeek K, Verdijk LB, Koopman R, Wodzig WK, Dendale P, et al. Long-term leucine supplementation does not increase muscle mass or strength in healthy elderly men. Am J Clin Nutr 2009; 89: 1468-75.
107. Koopman R, Verdijk L, Manders RJ, Gijsen AP, Gorselink M, Pijpers E, et al. Co-ingestion of protein and leucine stimulates muscle protein synthesis rates to the same extent in young and elderly lean men. Am J Clin Nutr 2006; 84: 623-32.
108. Koopman R, Verdijk LB, Beelen M, Gorselink M, Kruseman AN, Wagenmakers AJ, et al. Co-ingestion of leucine with protein does not further augment post-exercise muscle protein synthesis rates in elderly men. Br J Nutr 2008; 99: 571-80
109. Verdijk LB, Jonkers RA, Gleeson BG, Beelen M, Meijer K, Savelberg HH, et al. Protein supplementation before and ater exercise does not further augment skeletal muscle hypertrophy after resistance training in elderly men. Am J Clin Nutr 2009; 89: 608-16.
110. Chen Z, Bassford T, Green SB, Cauley JA, Jackson RD, LaCroix AZ, et al. Postmenopausal hormone therapy and body composition- a substudy of the estrogen plus progestin trial of the Women's Health Iitiative. Am J Clin Nutr 2005; 82: 651-6.
111. Dieli-Conwright CM, Spektor TM, Rice JC and Schroeder ET. Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells. Acta Physiol (Oxf) 2009; 197: 187-96.
112. Pöllänen E, Ronkainen PH, Suominen H, Takala T, Koskinen S, Puolakka J, et al. Muscular transcriptome in postmenopausal women with or without hormone replacement. Rejuven Res 2007; 10: 485-500.
113. Tenover JL. Testosterone and the aging male. J Androl 1997; 18: 103-6.
114. Bhasin S, Calof O, Storer TW, Lee M, Mazer N, Jasuja R, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for physical dysfunction in chronic illness and ageing. Nat Clin Pract Endocrinol Metab 2006; 2: 146-59.
115. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone gel study group. J Clin Endocrinol Metab 2000; 85: 2839-53.
116. Bhasin S, Storer TW, Javenbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2005; 283: 763-70.
117. Morley JE and Perry HM, 3rd. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med 2000; 135: 370-8.
118. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanism. Am J Physiol Endocrinol Metab 2002; 282: E601-E7.
119. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML and Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab 2006; 91: 3024-33.
120. Conboy IM, Conboy MJ, Smythe GM and Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003; 302: 1575-7.
121. Conboy IM, Conboy MJ, Wagners AJ, Girma ER, Weissman IL and Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433: 760-4.
122. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90: 678-88.
123. Florini JR, Ewton DZ and Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17: 481-517.
124. Le Roith D, Bondy C, Yakar S, Liu JL and Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.
125. Frost RA, Nystrom GJ and Lang CH. Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts. Endocrinology 2002; 143: 492-503.
126. Sotiropoulos A, Ohanna M, Kedzia C, Menon RK, Kopchick JJ, Kelly PA, et al. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proc Natl Acad Sci USA 2006; 103: 7315-20.
127. Giovannini S, Marzetti E, Borst SE and Leeuwenburgh C. Modulation of GH/IGF-I axis: Potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev 2008; 129: 593-601.
128. Andersen NB, Andreassen TT, Orskov H and Oxlund H. Growth hormone and mild exercise in combination increases markedly muscle mass and tetanic tension in old rats. Eur J Endocrinol 2000; 143: 409-18.
129. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002; 288: 2282-92.
130. Lange KH, Andersen JL, Beyer N, Isaksson F, Larsson B, Rasmussen MH, et al. GH administration changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly men. J Clin Endocrinol Metab 2002; 87: 513-23.
131. Giannoulis MG, Sonksen PH, Umpleby M, Breen L, Pentecost C, Whyte M, et al. The effects of growth hormone and/or testosterone in health elderly men: a randomized controlled trial. J Clin Endoctinol Metab 2006; 91: 477-84.
132. Philippou A, Maridaki M, Halapas A and Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 2007; 21: 45-54.
133. Clemmons DR. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol Metab 2009; 20: 349-56.
134. Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofibers hypertrophy in transgenic mice. J Biol Chem 1995; 270: 12109-16.
135. Musaró A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized Igf-I transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27: 195-200.
136. Barton ER, Morris L, Musaró A, Rosenthal N and Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157: 137-48.
137. Barton-Davis ER, Shoturma DI, Musaró A, Rosenthal N and Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 1998; 95: 15603-7.
138. Schertzer JD, Ryall JG and Lynch GS. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Am J Physiol Endocrinol Metab 2006; 291: E499-E505.
139. Gregorevic P, Plant DR and Lynch GS. Administration of insulin- like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve 2004; 30: 295-304.
140. Butterfield GE, Thompson J, Rennie MJ, Marcus R, Hintz RL and Hoffman AR. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol Endocrinol Metab 1997; 272: E94-E9.
141. Dardevet D, Sornet C, Attaix D, Baracos VE and Grizard J. Insulin-like growth factor-1 and insulin resistance in skeletal muscles of adult and old rats. Endocrinology 1994; 134: 1475-84.
142. Dirks AJ and Leeuwenburgh C. Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radic Biol Med 2004; 36: 27-39.
143. Lopez-Lluch G, Hunt N, Jones B, Zhu M, Jamieson H, Hilmer S, et al. Calorie restriction induces mitochondrial biogenesis and bio-energetic efficiency. Proc Natl Acad Sci USA 2006; 103: 1768-73.
144. Weindruch R, Kayo T, Lee CK and Prolla TA. Microarray profiling of gene expression in aging and its alteration by caloric restriction in mice. J Nutr 2001; 131: 918S-23S.
145. Phillips T and Leeuwenburgh C. Muscle fiber specific apoptosis and TNF- alpha signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB J 2005; 95: 668-70.
146. Payne AM, Dodds SL and Leeuwenburgh C. Life-long calorie restriction in Fischer 344 rats attenuates age-related loss in skeletal muscle-specific force and reduces extracellular space. J Appl Physiol 2003; 95: 2554-62.
147. Bevilacqua L, Ramsey JJ, Hagopian K, Weindruch R and Harper M-E, et al. Effects of short- and medium-term calorie restriction on muscle mitochondrial protein leak and reactive oxygen species production. Am J Physiol Endocrinol Metab 2004; 286: E852-E61.
148. Aspnes LE, Lee CM, Weindruch R, Chung SS, Roecker EB and Aiken JM. Caloric restriction reduces fiber loss and mitochondrial abnormalities in aged rat muscle. FASEB J 1997; 11: 573-81.
149. Baker DJ, Betik AC, Krause DJ and Hepple RT. No decline in skeletal muscle oxidative capacity with aging in long-term calorically restricted rats: Effects are independent of mitochondrial DNA integrity. J Gerontol A Biol Sci Med Sci 2006; 61: 675-84.
150. Marzetti E, Carter CS, Wohlgemuth SE, Lees HA, Giovannini S anderson B, et al. Changes in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restriction. Mech Ageing Dev 2009; 130: 272-80.
151. Colman RJ, Beasley TM, Allison DB and Weindruch R. Attenuation of sarcopenia by dietary restriction in rhesus monkeys. J Gerontol Biol Sci 2008; 63A: 556-9.
152. Dirks AJ and Leeuwenburgh C. Caloric restriction in humans: Potential pitfalls and health concerns. Mech Ageing Dev 2006; 127: 1-7.
153. Mosoni L, Breuille D, Buffiere C, Obled C and Mirand PP. Age-related changes in glutathione availability and skeletal muscle carbonyl content in healthy rats. Exp Gerontol 2004; 39: 203-10.
154. Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, et al. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol 2004; 39: 17-24.
155. Ishii N. Role of oxidative stress from mitochondria on aging and cancer. Cornea 2008; 26: S3-S9.
156. Dirks A and Leeuwenburgh C. Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 2002; 282: 553-60.
157. Ochoa JJ, Quiles JL, López-Frías M, Huertas JR and Mataix J. Effect of lifelong coenzyme Q10 supplementation on age-related oxidative stress and mitochondrial function in liver and skeletal muscle of rats fed on a polyunsaturated fatty acid (PUFA)-rich diet. J Gerontol A Biol Sci Med Sci 2007; 62: 1211-8.
158. Rebrin I, Zicker S, Wedekind KJ, Paetau-Robinson I, Packer L and Sohal RS. Effect of antioxidant-enriched diets on glutathione redox status in tissue homogenates and mitochondria of the senescence accerelated mouse. Free Radic Biol Med 2005; 39: 549-57.
159. Jacobs I. Dietary creatine monohydrate supplementation. Can J Appl Physiol 1999; 24: 503-14.
160. Heinanen K, Nanto-Salonen K, Komu M, Erkintalo M, Heinonen OJ, Pulkki K, et al. Muscle creatine phosphate in gyrate atrophy of the choroids and retina with hyperornithinaemia-clues to pathogenesis. Eur J Clin Invest 1999; 29: 426-31.
161. Levine S, Tikunov B, Henson D, LaManca J and Sweeney HL. Creatine depletion elicits structural, biochemical, and physiological adaptations in rat costal diaphragm. Am J Physiol 1996; 271: C1480-C6.
162. Bermon S, Venembre P, Sachet C, Valour S and Dolisi C. Effects of creatine monohydrate ingestion in sedentary and weight-trained older adults. Acta Physiol Scand 1998; 164: 147-55.
163. Eijnde BO, Van Leemputte M, Goris M, Labarque V, Taes Y, Verbessem P, et al. Effects of creatine supplementation and exercise training on fitness in men 55-75 yr old. J Appl Physiol 2003; 95: 818-28.
164. Brose A, Parise G and Tarnopolsky MA. Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. J Gerontol A Biol Sci Med Sci 2003; 58: 11-9.
165. Chrusch MJ, Chilibeck PD, Chad KE, Davison KS and Burke DG. Creatine supplementation combined with resistance training in older men. Med Sci Sports Exerc 2001; 33: 2111-7.
166. Gotshalk LA, Volek JS, Staron RS, Denegar CR, Hagerman FC and Kraemer WJ. Creatine supplementation improves muscular performance in older men. Med Sci Sports Exerc 2002; 34: 537-43.
167. Kreider RB, Ferreira M, Wilson M, Grindstaff P, Plisk S, Reinardy J, et al. Effects of creatine supplementation on body composition, strength, and sprint performance. Med Sci Sports Exerc 1998; 30: 73-82.
168. Tarnopolsky MA, Parise G, Yardley NJ, Ballantyne CS, Olatinji S and Phillips SM. Creatine-dextrose and protein-dextrose induce similar strength gains during training. Med Sci Sports Exerc 2001; 33: 2044-52.
169. Hespel P, OP't Eijnde B, Van Leemputte M, Ursø B, Greenhalf PL, Labarque V, et al. Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans. J Physiol 2001; 536: 625-33.
170. Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olsen JL, et al. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. J Physiol 2006; 573: 525-34.
171. Parise G, Mihic S, MacLennan D, Yarasheski KE and Tarnopolsky MA. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J Appl Physiol 2001; 91: 1041-7.
172. Rawson ES, Wehnert ML and Clarkson PM. Effects of 30 days of creatine ingestion in older men. Eur J Appl Physiol Occup Physiol 1999; 80: 139-44.
173. Rawson ES and Clarkson PM. Acute creatine supplementation in older men. Int J Sports Med 2000; 21: 71-5.
174. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652-8.
175. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 2005; 102: 12005-10.
176. Millay DP, Sargent MA, Osinska H, Baines CP, Elisabeth RB, Vuagniaux G, et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008; 14: 442-7.
177. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA and Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009; 297: C1124-C32.
178. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S and Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296: C1258-C70.